Cinchophen

Cinchophen

SCHEMBL25519

O=C(O)c1cc(-c2ccccc2)nc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 1.00
PDE10A Q9Y233 2/20 1.00
LMNA P02545 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
DHODH Q02127 6/20 0.93
POLB P06746 1/20 0.82
AKR1C3 P42330 1/20 0.77
AKR1C2 P52895 1/20 0.77
AKR1C1 Q04828 1/20 0.77
HSD17B10 Q99714 2/20 0.69
ALDH1A1 P00352 1/20 0.69
TP53 P04637 1/20 0.69
CYP1A2 P05177 1/20 0.69
CYP2C19 P33261 1/20 0.69
HIF1A Q16665 1/20 0.69
KMT2A Q03164 2/20 0.69
MEN1 O00255 1/20 0.69
GFER P55789 1/20 0.69
NPC1 O15118 1/20 0.69
RAB9A P51151 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cinchophen SCHEMBL7588217 1.00 KDM4E (1.00) KDM4EPDE10ALMNASMN1; SMN2DHODH
Cinchophen SCHEMBL29376617 1.00 KDM4E (1.00) KDM4EPDE10ALMNASMN1; SMN2DHODH
Cinchophen SCHEMBL10757475 0.98 KDM4E (0.97) KDM4EPDE10ALMNASMN1; SMN2DHODH
Cinchophen SCHEMBL4464779 0.98 KDM4E (0.97) KDM4EPDE10ALMNASMN1; SMN2DHODH
Cinchophen SCHEMBL4805149 0.98 KDM4E (0.97) KDM4EPDE10ALMNASMN1; SMN2DHODH
SCHEMBL29536364 0.97 DHODH (1.00) KDM4EPDE10ALMNASMN1; SMN2DHODH
Cinchophen SCHEMBL27543969 0.97 KDM4E (0.93) KDM4EPDE10ALMNASMN1; SMN2DHODH
SCHEMBL2467110 0.97 DHODH (1.00) KDM4EPDE10ALMNASMN1; SMN2DHODH
SCHEMBL29359819 0.91 KDM4E (0.83) KDM4EPDE10ALMNASMN1; SMN2DHODH
SCHEMBL18746 0.91 KDM4E (0.83) KDM4EPDE10ALMNASMN1; SMN2DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3449 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713340-A2 COMPOSITIONS AND METHODS FOR PEPTIDE-BASED MODULATORS OF HUMAN PAPILLOMAVIRUS ONCOPROTEIN E6 Calico Life Sciences LLC (US) 2026-03-25 EP claimed
CN-118271369-B Single/binuclear iridium complex with anti-saturation absorption capacity and preparation method and application thereof 南京工业大学 2025-04-18 CN claimed
EP-4525870-A1 METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT Corcept Therapeutics Incorporated (US) 2025-03-26 EP claimed
US-20240245659-A1 Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient CORCEPT THERAPEUTICS INCORPORATED (US) 2024-07-25 US claimed
CN-118271369-A Single/binuclear iridium complex with anti-saturation absorption capacity and preparation method and application thereof 南京工业大学 2024-07-02 CN claimed
US-20240200072-A1 Allogeneic Cartilage Regeneration Tarachon, LLC (US) 2024-06-20 US claimed
WO-2023225282-A1 METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT CORCEPT THERAPEUTICS INCORPORATED (US) 2023-11-23 WO claimed
US-20230372312-A1 Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient CORCEPT THERAPEUTICS INCORPORATED (US) 2023-11-23 US claimed
US-20230285282-A1 OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT OCULAR THERAPEUTIX INC (US) 2023-09-14 US claimed
EP-4236943-A1 OCULAR IMPLANT CONTAINING AN ACTIVE AGENT Ocular Therapeutix, Inc. (US) 2023-09-06 EP claimed
WO-1994003811-A1 IMMUNOLOGICAL DETECTION USING TWO DETECTABLE LABELS GEC-MARCONI LIMITED (GB) 1994-02-17 WO claimed
EP-0300461-B1 Aromatic heterocyclic peroxyacids AUSIMONT SPA (IT) 1994-01-12 EP claimed
WO-1994000130-A1 COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1994-01-06 WO claimed
EP-0466650-A2 Improvements in non-steroidal anti-inflammatory therapy WARNER-LAMBERT COMPANY (US) 1992-01-15 EP claimed
EP-0300461-A2 Aromatic heterocyclic peroxyacids AUSIMONT S.p.A. (IT) 1989-01-25 EP claimed
EP-0039051-B1 MANNICH-BASE HYDROXAMIC ACID PRODRUGS FOR THE IMPROVED BIOAVAILABILITY OF NON-STEROIDAL ANTI-INFLAMMATORY AGENTS, A PROCESS FOR PREPARING AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM MERCK & CO. INC. (US) 1985-07-24 EP claimed
US-4376767-A ANTIBIOTICS AND PHARMACEUTICALS MERCK & CO., INC. (US) 1983-03-15 US claimed
EP-0055870-A1 Pyridylmethyl esters of selected bio-affecting carboxylic acids, process for preparing and pharmaceutical composition comprising the same MERCK & CO. INC. (US) 1982-07-14 EP claimed
EP-0051278-A1 Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same MERCK & CO. INC. (US) 1982-05-12 EP claimed
EP-0039051-A2 Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them MERCK & CO. INC. (US) 1981-11-04 EP claimed